Hunting the source of renewable oocytes
20 July, 2006 by External Press Release AuthorFemale mammals may continue to proudce eggs throughout puberty and adulthood.
Positive phase I data for Novogen's bowel disease drug
02 March, 2006 by Ruth BeranA recently completed phase I clinical trial of biopharmaceutical company Novogen's (ASX:NRT) anti-inflammatory compound NV-52 has shown rapid absorption indicating its potential as an oral therapy, according to the company.
Zenyth in-licenses antibody patents from Ludwig
02 March, 2006 by Ruth BeranMelbourne's Zenyth Therapeutics (ASX:ZTL), formerly Amrad, has in-licensed patents from the Ludwig Institute for Cancer Research for antibodies that target a key part of the inflammatory process.
'Frustrating' delays for Chemeq's regulatory approval
02 March, 2006 by Ruth BeranRegulatory approval for Chemeq's (ASX:CMQ) polymeric antimicrobial CHEMEQ has been delayed in some jurisdictions, pushing expected registrations out in some cases to 2007.
CathRx files for cardiac catheters CE Mark
01 March, 2006 by Ruth BeranCathRx (ASX:CXD) has taken the first step in the CE Mark approval process for its cardiac diagnostic catheters.
Clinuvel begins controlled-release implant trial
01 March, 2006 by Ruth BeranMelbourne's Clinuvel Pharmaceuticals (ASX:CUV), formerly Epitan, has begun a trial in Adelaide of its lead drug CUV1647 in a controlled-release pellet form.
Peplin's phase IIa 'sun spot' trial positive, second BCC trial enrolment complete
28 February, 2006 by Helen SchullerPeplin (ASX:PEP) has reported preliminary results of its US-based phase IIa dose escalation clinical trial to establish the maximum tolerated dose of PEP005 in actinic keratosis (AK), also known as solar keratosis, a skin condition which can develop into skin cancer.
Rockeby to supply avian flu tests in Turkey, aims to raise $1.73m
28 February, 2006 by Ruth BeranSingapore-based Rockeby Biomed (ASX:RBY) has signed an exclusive deal to supply its avian flu kits to the Turkish Poultry Industry, an organisation which represents 90 per cent of the poultry industry in Turkey.
New company aims to take NZ agbiotech to the US
28 February, 2006 by Iain ScottAgResearch, the largest of New Zealand's crown research institutes, has formed a new company with San Diego venture capital firm Finistere Partners, to commercialise its plant genome technology in the US.
Epitan changes name to Clinuvel, announces new clinical program
27 February, 2006 by Ruth BeranMelbourne-based Epitan (ASX:EPT) will now be known as Clinuvel.
Zenyth posts smaller losses, revenues
24 February, 2006 by Ruth BeranMelbourne's Zenyth Therapeutics (ASX:ZTL), formerly Amrad, has posted a smaller loss for the half year to December 31, but also revealed a drop in revenues.
Solagran conifer extract granted TGA approval
23 February, 2006 by Helen SchullerBotanical biotech Solagran (ASX: SLA) has been granted approval from the Australian Therapeutic Goods Administration (TGA) for Bioeffective A as a new complementary medicinal substance for topical and internal use.
Norwood Immunology begins phase II of cancer trial
22 February, 2006 by Ruth BeranThe first of 80 patients have been enrolled in Norwood Immunology's (AIM:NIM) phase II clinical trial using its thymus-rejuvenating technology in cancer patients receiving self-derived (autologous) bone marrow transplants.
Bone completes first stage of osteoporosis drug trial
22 February, 2006 by Helen SchullerBone Medical (ASX:BNE) has reported that its oral parathyroid hormone (PTH) product Perthoxal, for the treatment of osteoporosis, proved safe and tolerable in a phase I trial.
CSL bird flu vaccine may be granted indemnity
21 February, 2006 by Ruth BeranThe federal government is considering whether to protect vaccine company CSL (ASX:CSL) against lawsuits by patients who suffer adverse reactions from its bird flu vaccine if production is fast-tracked in the event of pandemic.
